In keeping with the above hypothesis, the introduction of a KRAS mutation combined with the controlled induction of biallelic APC loss in our model has moved the development of the tumor more distally, from the small bowel to the proximal colon, while simultaneously changing the histology from a benign adenoma to a malignant adenocarcinoma. The gene discussed is KRAS; the disease is adenocarcinoma.